1. Home
  2. ALT vs NMAI Comparison

ALT vs NMAI Comparison

Compare ALT & NMAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALT
  • NMAI
  • Stock Information
  • Founded
  • ALT 1997
  • NMAI 2021
  • Country
  • ALT United States
  • NMAI United States
  • Employees
  • ALT N/A
  • NMAI N/A
  • Industry
  • ALT Biotechnology: Pharmaceutical Preparations
  • NMAI Investment Managers
  • Sector
  • ALT Health Care
  • NMAI Finance
  • Exchange
  • ALT Nasdaq
  • NMAI Nasdaq
  • Market Cap
  • ALT 397.4M
  • NMAI 422.8M
  • IPO Year
  • ALT N/A
  • NMAI N/A
  • Fundamental
  • Price
  • ALT $4.19
  • NMAI $12.64
  • Analyst Decision
  • ALT Strong Buy
  • NMAI
  • Analyst Count
  • ALT 6
  • NMAI 0
  • Target Price
  • ALT $18.20
  • NMAI N/A
  • AVG Volume (30 Days)
  • ALT 11.7M
  • NMAI 74.8K
  • Earning Date
  • ALT 08-07-2025
  • NMAI 01-01-0001
  • Dividend Yield
  • ALT N/A
  • NMAI 13.14%
  • EPS Growth
  • ALT N/A
  • NMAI N/A
  • EPS
  • ALT N/A
  • NMAI 0.64
  • Revenue
  • ALT $20,000.00
  • NMAI N/A
  • Revenue This Year
  • ALT N/A
  • NMAI N/A
  • Revenue Next Year
  • ALT $1,557,547.90
  • NMAI N/A
  • P/E Ratio
  • ALT N/A
  • NMAI $19.03
  • Revenue Growth
  • ALT N/A
  • NMAI N/A
  • 52 Week Low
  • ALT $2.90
  • NMAI $10.60
  • 52 Week High
  • ALT $11.16
  • NMAI $12.55
  • Technical
  • Relative Strength Index (RSI)
  • ALT 39.67
  • NMAI 58.32
  • Support Level
  • ALT $4.33
  • NMAI $12.54
  • Resistance Level
  • ALT $4.79
  • NMAI $12.73
  • Average True Range (ATR)
  • ALT 0.52
  • NMAI 0.11
  • MACD
  • ALT -0.16
  • NMAI 0.00
  • Stochastic Oscillator
  • ALT 26.92
  • NMAI 73.86

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

About NMAI Nuveen Multi-Asset Income Fund of Beneficial Interest

Nuveen Multi-Asset Income Fund is a closed-end management investment company. The Fund dynamically invests in a portfolio of equity and debt securities of issuers located around the world. This dynamic investment strategy uses a risk-based framework in which any amount can be allocated to an asset-class at any time. The Fund may invest in equity and debt securities of any type without limit.

Share on Social Networks: